🟢 HCW Biologics is trading 6.77% up in after-hours trading after Akron Biotech distribution deal

HCW Biologics is trading 6.77% up at $2.68 in after-hours trading after announcing an exclusive distribution agreement with Akron Biotech for HCW11-006.

• The agreement includes prepayment commitments and commercialization for CAR-T manufacturing applications.
• The regular session closed at $2.51 after falling 14.63%, making the rebound notable.
• No earnings release or FDA decision was identified; the agreement is the clearest company-specific catalyst.